Skip to Content
Search Menu

AAD 2026: Toward Precision Medicine in Psoriasis – What It Means for Patients

In this overview, Lars Werner, CEO of the Danish Psoriasis Association, reflects on the key takeaways from AAD 2026 and shares his perspective on how precision medicine, biomarkers, and new systemic treatments are reshaping psoriasis care and changing the understanding of psoriasis as a complex inflammatory disease.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

GLP-1RA Therapy Linked to Major Survival and Cardiovascular Benefits in Psoriasis Patients

/ Jan Andreasen
EADV25Psoriasis
Lone Skov

EADV 2024 – Still Unanswered Questions about Psoriasis and Psoriasis Treatment

/ Lone Skov
EADV24PsoriasisPsoriatic arthritis Play the Video 05:10

Deucravacitinib, A New Oral Option for Patients with Moderate to Severe Psoriasis

/ Sofie Pohl
Psoriasis
Andrew Blauvelt

LBA: Probably the Best in Class for Treatment of Plaque Psoriasis

/ Andrew Blauvelt
EADV24Psoriasis Play the Video 04:38
Christopher Willy Schwarz

Non-Medical Switches of Biosimilar in Psoriasis Treatment Appears Safe

/ Christopher Willy Schwarz
EADV24Psoriasis Play the Video 2:45
Melinda J Gooderham

Key Findings on Deucravacitinib – A New Oral Treatment for Psoriasis

/ Melinda J. Gooderham
EADV24Psoriasis Play the Video 02:51

EADV24: New Research Confirms Link Between Stress and Psoriasis Relapse

/ Sofie Pohl
EADV24Psoriasis
Prof. Matthias Augustin

The WHO-5 Questionnaire: Investigating the Well-Being Psoriasis Patients

/ Matthias Augustin
Psoriasis Play the Video 6:39

Significant Improvement of Quality-of-Life in Patients with Psoriasis

/ Matthias Augustin
Psoriasis Play the Video 05:30
Back to top